Bosh sahifaBEAM • NASDAQ
add
Beam Therapeutics Inc
Yopilish kursi
19,93 $
Kunlik diapazon
19,31 $ - 20,27 $
Yillik diapazon
13,53 $ - 35,25 $
Bozor kapitalizatsiyasi
2,04 mlrd USD
Oʻrtacha hajm
2,59 mln
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 30,07 mln | -90,49% |
Joriy xarajat | 28,66 mln | -33,74% |
Sof foyda | -90,35 mln | -163,27% |
Sof foyda marjasi | -300,51 | -765,43% |
Har bir ulushga tushum | -1,09 | -163,01% |
EBITDA | -94,59 mln | -168,44% |
Amaldagi soliq stavkasi | 0,00% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 850,74 mln | -28,50% |
Jami aktivlari | 1,10 mlrd | -24,38% |
Jami passivlari | 370,28 mln | -22,60% |
Umumiy kapital | 733,54 mln | — |
Tarqatilgan aksiyalar | 81,11 mln | — |
Narxi/balansdagi bahosi | 2,20 | — |
Aktivlardan daromad | -21,98% | — |
Kapitaldan daromad | -27,06% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | dek, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -90,35 mln | -163,27% |
Operatsiyalardan naqd pul | -76,36 mln | -156,54% |
Sarmoyadan naqd pul | 126,28 mln | 28,73% |
Moliyadan naqd pul | 3,44 mln | -89,78% |
Naqd pulning sof oʻzgarishi | 53,36 mln | -80,01% |
Boʻsh pul | -22,18 mln | -123,15% |
Haqida
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of off-target effects compared to previous CRISPR-based methods. Wikipedia
CEO
Tashkil etilgan
2017
Sayt
Xodimlar soni
483
